Recent Analysts’ Ratings Changes for Glaukos (GKOS)

Several analysts have recently updated their ratings and price targets for Glaukos (NYSE: GKOS):

  • 3/12/2019 – Glaukos was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Glaukos Corporation is an ophthalmic medical technology company. The Company develops, manufactures and markets medical devices for the treatment of glaucoma. Its product pipeline consists of iStent Inject, the iStent Supra and iDose. The company operates primarily in United States, Germany, Europe, the Asia Pacific, Canada and internationally. Glaukos Corporation is headquartered in Laguna Hills, California. “
  • 3/8/2019 – Glaukos is now covered by analysts at BTIG Research. They set a “neutral” rating and a $66.02 price target on the stock.
  • 3/4/2019 – Glaukos was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. They now have a $74.00 price target on the stock. According to Zacks, “Glaukos Corporation is an ophthalmic medical technology company. The Company develops, manufactures and markets medical devices for the treatment of glaucoma. Its product pipeline consists of iStent Inject, the iStent Supra and iDose. The company operates primarily in United States, Germany, Europe, the Asia Pacific, Canada and internationally. Glaukos Corporation is headquartered in Laguna Hills, California. “
  • 2/28/2019 – Glaukos had its price target raised by analysts at Stifel Nicolaus from $58.00 to $68.00. They now have a “positive” rating on the stock.
  • 2/28/2019 – Glaukos had its price target raised by analysts at Stephens from $70.00 to $80.00. They now have an “overweight” rating on the stock.
  • 2/28/2019 – Glaukos had its “overweight” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $80.00 price target on the stock.

Glaukos stock opened at $69.30 on Friday. The stock has a market cap of $2.58 billion, a P/E ratio of -187.30 and a beta of 1.63. Glaukos Corp has a 52 week low of $26.75 and a 52 week high of $75.51.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Wednesday, February 27th. The medical instruments supplier reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.17. The firm had revenue of $54.08 million during the quarter, compared to analysts’ expectations of $49.60 million. Glaukos had a negative return on equity of 8.24% and a negative net margin of 7.14%. The firm’s quarterly revenue was up 29.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.03 EPS. As a group, analysts expect that Glaukos Corp will post -0.33 earnings per share for the current year.

In other Glaukos news, COO Chris M. Calcaterra sold 90,000 shares of Glaukos stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $67.69, for a total value of $6,092,100.00. Following the completion of the sale, the chief operating officer now owns 193,344 shares in the company, valued at approximately $13,087,455.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Joseph E. Gilliam sold 5,000 shares of Glaukos stock in a transaction dated Tuesday, February 19th. The shares were sold at an average price of $70.03, for a total value of $350,150.00. The disclosure for this sale can be found here. Company insiders own 11.60% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the business. Oppenheimer Asset Management Inc. purchased a new stake in Glaukos in the 4th quarter valued at about $31,000. NumerixS Investment Technologies Inc grew its holdings in shares of Glaukos by 20.7% during the 4th quarter. NumerixS Investment Technologies Inc now owns 1,100 shares of the medical instruments supplier’s stock worth $61,000 after purchasing an additional 189 shares during the period. Rehmann Capital Advisory Group purchased a new stake in shares of Glaukos during the 3rd quarter worth about $63,000. Strs Ohio purchased a new stake in shares of Glaukos during the 4th quarter worth about $78,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Glaukos by 24.5% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,583 shares of the medical instruments supplier’s stock worth $145,000 after purchasing an additional 508 shares during the period.

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma.

Further Reading: How a Strangle Strategy is different from a Straddle Strategy

Receive News & Ratings for Glaukos Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corp and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

Leave a Reply